TABLE 6.

Ketamine (K) and nor-ketamine (N-K) pharmacokinetic parameters (geometric mean and standard deviation)

D (mg)	K			N-K			C max	K		N-K		K			N-K		AUC
Route	Cmax(ng/mU	Cmax/D	n	Cmax (ng/ml)	Cmax/D	n	MRa N-K/K	Tmax(min)	n	Tmax(min)	n	AUC (μg·h/L)	AUC/D	F(%)	AUC (μg·h/L)	AUC/D	MR N-K/K
10 IV	296 (1.71)	29.6	9	2.8 (1.86)	2.7	8	0.089 (1.6)	2 (1)	9	30 (1)	8	113	678	100	22	130	0.19
10 IN	22.9 (1.97)	2.3	7	17.8 (1.89)	1.8	5	0.78	23 (3.0)	7	79 (1.86)	5	19	116	17	n/a
30 IN	60.8 (1.90)	2.0	10	68.1 (1.80)	2.3	10	1.12 (1.72)	14 (3.8)	10	60 (1.76)	10	46	91	13	181	361	3.95
50 IN	77.6 (2.29)	1.6	10	105 (1.63)	2.1	10	1.35 (2.37)	16 (4.4)	10	56 (1.83)	10	64	77	11	291	350	4.54

Abbreviations: μg·h/L, (microgram per hour) per liter; AUC, area under the curve; C_max, maximum concentration; D, dose; F, bioavailability; ml, milliliter; ng, nanogram; T_max, time to reach maximum concentration.

^aC_max metabolic ratios (MR) were calculated at the individual level, allowing for calculation of geometric mean and standard deviation values by dose level. For the 10-mg IN group, there were only three patients with both ketamine (K) and nor-ketamine (NK) truly informed values, which prompted us to report the ratio of the geometric mean of nor-ketamine over the geometric mean of ketamine. For the 10-mg IV, 30-mg IN, and 50-mg IN groups, the geometric mean of individual level metabolic ratio and ratio of geometric means were near-identical.